Last reviewed · How we verify
Atropine 0.04%
Atropine blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity.
Atropine blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity. Used for Mydriasis (pupil dilation) for ophthalmic examination, Cycloplegia (ciliary muscle paralysis) for refraction testing, Myopia control in children.
At a glance
| Generic name | Atropine 0.04% |
|---|---|
| Sponsor | Beijing Tongren Hospital |
| Drug class | Anticholinergic agent / Muscarinic antagonist |
| Target | Muscarinic acetylcholine receptors (M1-M5) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Atropine is an anticholinergic agent that competitively antagonizes acetylcholine at muscarinic receptors throughout the body. By blocking these receptors, it reduces parasympathetic effects including pupil constriction, accommodation, and excessive salivation or secretions. The 0.04% ophthalmic formulation is primarily used to dilate the pupil and relax the ciliary muscle for diagnostic and therapeutic purposes.
Approved indications
- Mydriasis (pupil dilation) for ophthalmic examination
- Cycloplegia (ciliary muscle paralysis) for refraction testing
- Myopia control in children
Common side effects
- Blurred vision
- Photophobia (light sensitivity)
- Eye irritation or discomfort
- Increased intraocular pressure
- Systemic anticholinergic effects (dry mouth, tachycardia) if absorbed
Key clinical trials
- The Effect and Safety of Different Doses of Atropine on Myopic Progression of Highly Myopic Children: Multi-centered Randomized Clinical Trial (NA)
- Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia (PHASE4)
- Pathophysiology of Orthostatic Intolerance (NA)
- Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control (PHASE1, PHASE2)
- Auricular Acupressure Reduces Rebound Effects After Discontinuation of Atropine (NA)
- Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery (NA)
- Effects of Neostigmine-dose on Diaphragmatic Dynamics (PHASE1)
- The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atropine 0.04% CI brief — competitive landscape report
- Atropine 0.04% updates RSS · CI watch RSS
- Beijing Tongren Hospital portfolio CI